LLLT (Low level laser therapy) is a painless, sterile, non-invasive, drug-free treatment which is used to treat a variety of pain syndromes, injuries, wounds, fractures, neurological conditions and pathologies. Laser therapy can be used any time a patient requests or needs a drug­less procedure for the control of pain, when conventional therapies have been ineffective, or when the acceleration of healing from injuries is desired.

  • Biostimulation, including improved metabolism & increased cell metabolism
  • Improved blood circulation and vasodilatation
  • Analgesic effect
  • Anti-edematous effects Anti-inflammatory and
  • Stimulation of wound healing
  • Relieves acute and chronic pains
  • Increases the speed, quality and tensile strength of tissue repair
  • Increases blood supply
  • Stimulates the immune system
  • Stimulates nerve function
  • Develops collagen and muscle tissue
  • Helps generate new and healthy cells and tissue
  • Promotes faster wound healing and clot formation
  • Reduces inflammation

The ML830®

The MLA830 is a GaAlA Laser that has wavelength of 830 nm with a power output of 90 mw. At this wavelength and power the ML830® Laser has a penetration of approximately 5 cm or 2 inches.

It is not an accident that the Microlight Corporation of America chose & patented the 830nm technology for its ML830®. There are 30+ years of clinical studies that proved the 830nm range is the optimal wave-length. No other Low-Level Laser offers this superior amount of penetration of tissue!


​As further background, General Motors had serious problems with Carpal Tunnel Syndrome among its workers. GM responded by conducting a 36-week double-blind study, using the ML830® to see if non-invasive conjunctive therapy would help. Among the 166 afflicted GM workers who entered the program, those treated with the ML830® laser showed significant improvement in grip strength and range of motion when compared to other GM workers who were treated with placebo lasers.

A prominent medical school in Houston conducted a similar double-blind study on CTS in 1998 that showed a 70% improvement after conjunctive therapy using the ML830® among those patients in the active group.

If you have any questions about our services, please contact us today at (817) 523-9590.